Publications

1. Advice - reimburse selumetinib (Koselugo®) for the treatment of benign tumours in children with neurofibromatosis type 1 (NF1)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse selumetinib ...

   Report | 25-04-2024

2. Advice - Reimburse lisocabtagene maraleucel (Breyanzi®) for the treatment of lymphoma

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lisocabtagene ...

   Report | 11-04-2024

3. Advice - Reimburse deucravacitinib (Sotyktu®) for the treatment of moderate-to-severe psoriasis

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse deucravacitinib ...

   Report | 27-03-2024

4. Advice - Reimburse bulevirtide (Hepcludex®) for the treatment of chronic hepatitis delta virus (HDV) infection in certain patients

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse bulevirtide ...

   Report | 13-03-2024

5. Advice - reimburse upadacitinib (Rinvoq®) for the treatment of Crohn's disease

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse upadacitinib ...

   Report | 01-03-2024

6. International agenda

   The international agenda describes the work of the National Health Care Institute in the international field. We collaborate with ...

   Report | 01-03-2024

7. Advice - Early discontinuation of conditional inclusion of medicinal products rhPTH 1-84 (Natpar®) and ataluren (Translarna®)

   The National Health Care Institute advises the Minister for Medical Care to discontinue the conditional inclusion of the ...

   Report | 21-02-2024

8. Advice - Extension of reimbursement conditions for solriamfetol (Sunosi®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the List 2 conditions ...

   Report | 16-02-2024

9. Package advice on the lock procedure medicinal product olaparib (Lynparza®) for the treatment of hereditary breast cancer

   The National Health Care Institute has assessed whether the medicinal product olaparib (Lynparza®) can be reimbursed from the ...

   Report | 13-02-2024

10. Guideline for economic evaluations in healthcare (2024 version)

    More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...

    Report | 16-01-2024